How Can Healthcare Organizations Earn Trust with Marginalized Communities?
Access to care isn't enough. Healthcare organizations need to build trust in order to reach underserved communities, experts said on a recent panel.
Digital Therapeutics Sector Sees Billing Codes as Key to Breaking Free of Reimbursement Rut
Medicare’s physician fee schedule includes billing codes for digital therapeutics for the first time. Stakeholders say these codes could help turn around reimbursement challenges weighing on the entire digital medicines sector.
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Advocates of Digital Therapies Hope Bill Can Ease Reimbursement
A similar bill appeared last year but did not progress. Given the potential costs of reimbursing prescription digital therapeutics, Congress could be skeptical. Still, with growing attention on mental health, advocates are optimistic.
CEO of digital therapeutics business Freespira talks about its approach to anxiety disorders
Freespira CEO Dean Sawyer said its FDA cleared digital therapeutic is the first that's proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder, and PTSD, in a single, 28-day treatment episode.
Highmark expands access to device that helps manage panic, PTSD symptoms
The payer is expanding access to telehealth coaching for Freespria's digital device, which aims to eliminate or reduce symptoms of panic disorders and post-traumatic stress disorder.
Can Highmark successfully commercialize the healthcare innovation process?
Highmark Health is turning its internal VITAL Innovation program into a commercial offering meant to help startups test their products in real-world clinical environments.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.